- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00041964
A Study of HIV Levels During Pregnancy and After Childbirth
A Prospective Observational Study of Virologic and Immunologic Changes in HIV-Infected Women During the Postpartum Period
The purpose of this study is to find out if HIV-infected pregnant women taking anti-HIV drugs have an increased amount of HIV in their blood (viral load) after having the baby.
The purpose of A5153s, a substudy of A5150, is to characterize two anti-HIV drugs (nelfinavir [NFV] and lopinavir/ritonavir [LPV/r]) in HIV-infected women during pregnancy and after childbirth.
Sometimes pregnant women have an increase in their HIV viral load after their baby is born. This study will try to find out how often this happens. It will also examine possible reasons why the increase in viral load occurs.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Limited data suggest that HIV-infected pregnant women develop postpartum viral rebound. However, viral load changes in the postpartum period have not been adequately characterized. Changes in adherence to antiretroviral therapy, pregnancy-related changes in pharmacokinetics of antiretroviral medications, and decline in immune competence are mechanisms by which postpartum viral load rebound may occur. This study is designed to characterize the incidence and magnitude of postpartum viral rebound during the initial 24 weeks postpartum and to explore the mechanisms and consequences of viral rebound.
Eligible patients are evaluated at gestational weeks 34 and 36, at delivery, and at regular visits for 96 weeks postpartum. Most evaluations include a medical history, physical exam, laboratory tests, and adherence and quality-of-life questionnaires. Viral load and CD4/CD8 cell counts are measured frequently.
Patients are expected to receive at least 8 weeks of stable HAART before delivery, and to continue HAART throughout the remainder of the study. The choice of HAART is left to the primary provider. No antiretroviral drugs are provided by this study.
Patients participating in the A5153s substudy receive either NFV or LPV/r as part of their HAART. Pharmacokinetic blood sampling takes place at 36 weeks gestation, 6 weeks postpartum, and 24 weeks postpartum. Patients record the administration times and doses of their NFV or LPV/r for 48 hours prior to each substudy visit, and hold their regularly scheduled doses of antiretroviral medications on substudy days. Patients arrive at the clinic fasting (no food or drink for the previous 8 hours) and are given a standardized breakfast prior to supervised administration of their NFV or LPV/r dose. An intravenous catheter is placed in an arm vein for blood collection at pre-dose and 1, 2, 4, and 6 hours post-dose.
Tipo di studio
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
San Juan, Porto Rico
- San Juan City Hosp
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- Univ of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Stati Uniti, 90095-1793
- UCLA School of Medicine
-
Los Angeles, California, Stati Uniti, 90033
- Los Angeles County Medical Center/USC
-
San Diego, California, Stati Uniti, 92103
- UCSD Mother, Child & Adolescent HIV Program
-
San Francisco, California, Stati Uniti, 94110
- San Francisco General Hosp
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32209
- Univ of Florida- Health Science Ctr
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory Univ
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 98616-2396
- University of Hawaii
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, Stati Uniti, 60611-3015
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60612
- Cook County Hosp Core Ctr
-
Chicago, Illinois, Stati Uniti, 60614
- Chicago Childrens Memorial Hospital (Pediatric)
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana Univ Hosp
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Childrens Hospital of Michigan
-
Detroit, Michigan, Stati Uniti, 48201-1427
- Hutzel Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455-0392
- Hennepin County Med Clinic
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07103
- Univ of Med & Dentistry of NJ/Univ Hosp
-
-
New York
-
Bronx, New York, Stati Uniti, 10461
- Jacobi Med Ctr
-
New York, New York, Stati Uniti, 10032-3784
- Columbia University
-
New York,, New York, Stati Uniti, 10016-6481
- NYU/Bellevue
-
Stony Brook, New York, Stati Uniti, 11794-8111
- State Univ of New York at Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Univ of North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke Univ Med Ctr
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve Univ
-
Cleveland, Ohio, Stati Uniti, 44109-1998
- MetroHealth Med Ctr
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213-2582
- University of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02906
- Miriam Hosp / Brown Univ
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38105-2794
- The Regional Med Ctr, Memphis
-
Nashville, Tennessee, Stati Uniti, 37203
- Comprehensive Care Clinic
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235-9173
- University of Texas, Southwestern Medical Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Univ of Washington (Seattle)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
Patients may be eligible for this study if they:
- Are age 13 or older.
- Are between 22 and 30 weeks pregnant.
- Have had their pregnancy confirmed by ultrasound at 14 weeks gestation or later.
- Are infected with HIV.
- Are planning to receive at least 8 weeks of highly active antiretroviral therapy (HAART) by the time they have their baby.
- Are available for follow-up for the duration of the study.
Exclusion Criteria
Patients may not be eligible for this study if they:
- Intend to terminate their pregnancy.
- Intend to breast-feed their baby.
- Are carrying a baby with major abnormalities, including spina bifida, anencephaly, hydrops, or ascites.
- Have taken certain medications.
- Are enrolled in other studies that require large blood draws.
- Will be taking anti-HIV drugs only to prevent mother-to-child transmission of HIV, and not to treat the maternal infection itself.
- Actively abuse drugs or alcohol in a way that would interfere with participation in the study.
Piano di studio
Come è strutturato lo studio?
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Beverly Sha
- Cattedra di studio: Alice Stek
Pubblicazioni e link utili
Pubblicazioni generali
- Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):232-6. doi: 10.1097/00042560-199703010-00006.
- Rich KC, Siegel JN, Jennings C, Rydman RJ, Landay AL. CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis. 1995 Nov;172(5):1221-7. doi: 10.1093/infdis/172.5.1221.
- Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, Song JL, Jin Z, Zhao JQ, Clapp S, Chen IS, Ho DD, Ammann AJ. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997 May;3(5):549-52. doi: 10.1038/nm0597-549.
- Burns DN, Landesman S, Minkoff H, Wright DJ, Waters D, Mitchell RM, Rubinstein A, Willoughby A, Goedert JJ. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol. 1998 Feb;178(2):355-9. doi: 10.1016/s0002-9378(98)80025-2.
- Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A; Aids Clinical Trials Group ACTG A5150 Team. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb;12(1):9-23. doi: 10.1310/hct1201-9.
Studiare le date dei record
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Infezioni da HIV
Altri numeri di identificazione dello studio
- ACTG A5150
- ACTG A5153s
- AACTG A5150
- AACTG A5153s
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
Erasmus Medical CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1 | Infezione da HIV IOlanda
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun e altri collaboratoriSconosciutoHIV | Bambini non infetti da HIV | Bambini esposti all'HIVCamerun
-
Midway Specialty Care CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1Stati Uniti
-
University of MinnesotaCompletatoInfezioni da HIV | HIV | ImmunodeficienzaStati Uniti
-
Fred Hutchinson Cancer CenterInstitute for the Development of AfricaCompletatoInfezioni da HIV | Coinfezione HIV-1 e HSV-2Camerun
-
Allegheny Singer Research Institute (also known...Attivo, non reclutanteInfezioni da HIV | Infezione da HIV-1 | Infezione da HIV IStati Uniti
-
University of California, DavisCompletato
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completato